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Long noncoding RNAs are emerging players in the epigenetic machinery with key roles
in development and diseases. Here we uncover a complex network comprising a
promoter-associated noncoding RNA (paRNA), microRNA and epigenetic regulators that
controls transcription of the tumour suppressor E-cadherin in epithelial cancers. E-cadherin
silencing relies on the formation of a complex between the paRNA and microRNA-guided
Argonaute 1 that, together, recruit SUV39H1 and induce repressive chromatin modiﬁcations in
the gene promoter. A single nucleotide polymorphism (rs16260) linked to increased cancer
risk alters the secondary structure of the paRNA, with the risk allele facilitating the assembly
of the microRNA-guided Argonaute 1 complex and gene silencing. Collectively, these data
demonstrate the role of a paRNA in E-cadherin regulation and the impact of a noncoding
genetic variant on its function. Deregulation of paRNA-based epigenetic networks may
contribute to cancer and other diseases making them promising targets for drug discovery.
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T
he human genome is pervasively transcribed generating a
large number of non-coding transcripts, called non-coding
RNAs (ncRNAs), most with yet undeﬁned function1,2.
Long intergenic ncRNAs (lincRNAs) and natural antisense
transcripts (NATs) have been shown to act as guides for
recruitment of epigenetic effectors to speciﬁc genomic sites and
have been implicated in transcriptional reprogramming
during development and disease1,3,4. High-throughput
RNA sequencing efforts have revealed that long ncRNAs are
also transcribed in promoter-proximal regions of most annotated
genes5–8. Promoter–proximal transcripts (hereafter referred as
promoter-associated RNAs, paRNAs) might act as cis-acting
elements in transcriptional regulation of neighbouring genes but
their molecular and functional characterization is still largely
lacking9. An intriguing question is whether genetic variants, like
single-nucleotide polymorphisms (SNPs), in promoter regions
affect the function of promoter-proximal transcripts. Several
disease-associated SNPs map to noncoding regions, including
promoters10–13, and may underlie allele-speciﬁc differences in the
local epigenetic landscape by altering DNA elements, like
transcription factor-binding sites14–16. However, a clear
mechanistic link between noncoding SNPs and transcriptional
regulation is in many cases missing17.
In this study, we examine the transcriptional landscape within
the promoter–proximal region of the gene encoding E-cadherin
(CDH1), an important epithelial cell differentiation and tumour
suppressor protein18. CDH1 is epigenetically silenced in
many epithelial cancers and this event is associated with the
epithelial-to-mesenchymal transition (EMT) and the acquisition
of cancer stem-like cell (CSC) properties, key features in tumour
progression18. We ﬁnd that silencing of CDH1 involves the
formation of a microRNA (miRNA)-guided Argonaute 1 (AGO1)
complex on a sense promoter-proximal transcript with
consequent recruitment of SUV39H1 and repressive chromatin
modiﬁcations. We provide evidence that a cancer-associated SNP
inﬂuences this paRNA-based regulatory network by modifying
the secondary structure of the sense transcript within the
miRNA/AGO1 binding region, thereby increasing the
accessibility of the miRNA/AGO1 complex to the paRNA and
the CDH1 promoter. Altogether, we show the involvement of
paRNAs in the transcriptional regulation of a key tumour
suppressor gene and how the impact of a functional noncoding
genetic variant on epigenetic gene silencing and tumour
progression is mediated by the effect on the secondary structure
of a promoter-proximal transcript. Our work suggests that
deregulation of paRNA-based transcriptional mechanisms could
contribute to epigenetic silencing of tumour suppressor genes and
disease progression in cancer patients.
Results
Promoter-proximal transcripts at the CDH1 gene locus.
We applied transcript prediction tools in the Hypergeometric
Optimization of Motif EnRichment (HOMER) suite for
Motif Discovery and next-generation sequencing analysis19 to a
compendium of GRO-Seq data sets20–23 from human cell lines to
examine the transcriptional landscape at the CDH1 promoter.
Antisense (AS) and sense (S) oriented transcripts were predicted
with high reproducibility in different cell lines (Fig. 1a). All the cell
lines exhibited promoter-associated transcripts in the AS orientation
relative to the gene transcription start site (TSS), consistent with the
presence of bidirectional transcripts at many active promoters.
Along with the AS transcripts, we detected also low levels of
S-oriented transcripts in the CDH1 promoter in HCT116 cells
(Supplementary Fig. 1a). Interestingly, HCT116 cells had the lowest
CDH1 expression in this cell line panel (Supplementary Fig. 1b).
To verify these predictions, we examined the presence of
promoter-proximal transcripts in a panel of prostate cancer cell
lines with differential CDH1 expression (Fig. 1b). Using
quantitative reverse transcription PCR (qRT–PCR), we detected
paRNAs with cumulative levels proportional to CDH1 expression
(Fig. 1c). Strand-speciﬁc RT–PCR showed that LNCaP cells, with
the highest CDH1 expression, exhibit prevalently AS-paRNA
(Fig. 1d). Conversely, PC3 and DU145 cells with low CDH1
expression had a greater amount of S-paRNA relative to
AS-paRNA.
We further evaluated the relationship between paRNA and
CDH1 expression in normal and tumorigenic prostate epithelial
cells (PrECs). We showed previously that knockdown of the
transcription factor ESE3/EHF (EHF) in PrECs induces a
tumorigenic phenotype along with EMT, CSC-like properties
and CDH1 repression24. We ﬁnd that repression of E-cadherin in
the tumorigenic EHFkd-PrECs is associated with decreased
AS-paRNA and increased S-paRNA expression (Fig. 1e).
Notably, human prostate tumours, which exhibit signiﬁcantly
lower E-cadherin expression compared to normal PrECs, have
almost invariably a higher level of S-paRNA than AS-paRNA
(Fig. 1f). Thus, both in cell lines and human samples, the relative
abundance of S-paRNA and AS-paRNA characterizes distinct
states of the CDH1 gene and the prevalence of S-paRNA is
associated with attenuated CDH1 transcription.
30-termini of CDH1 promoter-associated transcripts. We
examined the cellular distribution of paRNA by performing
strand-speciﬁc RT–PCR on RNA extracted from PC3, DU145
and LNCaP cells after subcellular fractionation. S and AS-paR-
NAs are mainly nuclear and chromatin-bound (Fig. 1g), con-
sistent with an epigenetic function. Interestingly, the chromatin
fraction contains exclusively S-paRNA in PC3 and DU145 cells
and AS-paRNA in LNCaP cells. To establish whether the paRNA
are poly-adenylated, we compared the level of the transcripts
detected by retro-transcribing either total or poly(A)þ RNAs.
Compared to b-actin mRNA, the majority of promoter
transcripts does not have poly(A) tails, and only a minor portion
is poly-adenylated in PC3 (B40%) and LNCaP (B20%) cells
(Supplementary Fig. 2a).
We next performed 30 rapid ampliﬁcation of cDNA ends
(30RACE) after adding poly(A) tails to total RNA extracted from
PC3 and LNCaP cells. A single prominent AS transcript is
detected in LNCaP cells with a unique termination site  456 bp
from the CDH1 TSS (Supplementary Fig. 2b). Conversely,
30RACE for the S transcript reveals multiple transcripts in PC3
cells with termination sites extending up to  54 and  10 bp
upstream the CDH1 TSS. These ﬁndings indicate that the
S-oriented transcripts are independent and not extended variants
of CDH1 mRNA.
To verify whether the heterogeneity of the 30-ends of the S
transcripts is due to progressive degradation, we knocked down
Rrp44, a core subunit of the exosome6. The level of S-paRNA in
PC3 cells increases after Rrp44 knockdown indicating that
degradation by the exosome contributes to the low steady-state
level and the progressive shortening of the sense transcript
(Supplementary Fig. 2c). Interestingly, 30RACE performed on the
soluble nuclear RNA fraction shows an increasing number of
shorter transcripts ending further upstream of the TSS ( 150 to
 220 bp), suggesting that transcripts detached from chromatin
are more susceptible to degradation by the exosome.
Promoter-associated transcript initiation sites. The consistent
location of the 50 termini of the transcripts predicted by GRO-Seq
data analysis in multiple cell lines suggests the presence of speciﬁc
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Figure 1 | Promoter-associated transcripts at the CDH1 gene locus. (a) Predicted promoter-proximal transcripts with sense (blue) and antisense (red)
orientation relative to the CDH1 gene from GRO-Seq data in multiple cell lines. (b,c) Level of CDH1 mRNA (b) and paRNA (c) in prostate cancer cell lines
determined by qRT-PCR. (d) S- and AS-paRNAs in prostate cancer cell lines determined by strand-speciﬁc RT–PCR. RT, control reaction without RTstep.
(e) Levels of CDH1 mRNA and paRNAs in normal PrECs and tumorigenic ESE3kd-PrECs determined by qRT–PCR (top) and strand-speciﬁc RT–PCR
(bottom). (f) S-paRNA (blue bars), AS-paRNA (red bars) and CDH1 mRNA (yellow bars) determined by qRT-PCR in human prostate tumours. Dotted
line, CDH1 mRNA level in normal PrECs shown as reference. (g) Intracellular distribution of S- and AS-paRNA in prostate cancer cell lines. (h) S and AS
transcript initiation sites in the CDH1 promoter determined by 50-RACE (see Supplementary Fig. 2d). (i) Luciferase reporter activity (left) and
promoter–proximal transcripts (right) generated from the full length CDH1 promoter construct in prostate cancer cell lines. (j) Schematic representation of
S-TSS and AS-TSS promoter reporter constructs and luciferase activity in PC3 and LNCaP cells. (k) S and AS transcripts generated from S-TSS and AS-TSS
constructs in PC3 and LNCaP cells determined by strand-speciﬁc RT–PCR. Positions of forward and reverse primers for RT–PCR are indicated in j. Data are
mean±s.d. of three independent determinations. Student’s t-test was used for P value assessment. *Po0.05.
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initiation events in the CDH1 promoter (Fig. 1a). We performed
50 rapid ampliﬁcation of cDNA ends (50RACE) to determine the
50-termini of the S and AS transcripts in PC3 and LNCaP cells. In
both cell lines, a single transcript is detected in either S or AS
orientation. Sequencing of the 50RACE products reveals that the
50-end of the S transcript is located  720 bp from the CDH1
TSS, while the 50 end of the AS transcript maps to  135 bp from
the CDH1 TSS (Supplementary Fig. 2d). Both S and AS transcript
initiation sites agree with the 50-termini predicted from GRO-seq
data (Fig. 1h). Furthermore, the position of the AS-paRNA
initiation site (AS-TSS) is within the range (r250 bp) reported by
others for promoter–proximal AS transcripts25,26.
These results support the presence of precise and independent
S and AS-transcript initiation sites in the CDH1 promoter. To
test this hypothesis, we turned to a CDH1 promoter reporter
construct and found that it reproduces the activity of the native
promoter along with the distinctive pattern of noncoding
transcripts in each cell line (Fig. 1i). Next, we cloned the
fragments encompassing the putative sense (S-TSS,  790 to
 709) and antisense (AS-TSS,  57 to  280) initiation sites
in a promoter-less luciferase reporter (Fig. 1j, left panels).
The AS-TSS and S-TSS reporters exhibit promoter activity in
LNCaP and PC3 cells, respectively (Fig. 1j, middle panels).
Conversely, constructs in opposite orientation (S-TSS and
AS-TSS) are not active in the same cells (Fig. 1j, right panels).
These ﬁndings were conﬁrmed by detecting with RT-PCR the
chimeric transcripts produced by AS-TSS and S-TSS reporters in
LNCaP and PC3 cells (Fig. 1k). Thus, the cloned promoter
fragments were able to drive transcription directionally and
independently of the gene TSS in the proper cell context. Control
experiments demonstrated that the transcripts derived from the
reporter constructs (Supplementary Fig. 2e). Furthermore,
deletion of the upstream region ( 790 to  373) containing
the S-TSS abolished transcription of S-paRNA in PC3 cells
but allowed the synthesis of AS-paRNA in LNCaP cells
(Supplementary Fig. 2f), consistent with independent regulation
of the S and AS-transcript initiation sites in the promoter-
proximal regions of the CDH1 gene.
Sense promoter-associated RNA silences CDH1. The
differential expression of S and AS-paRNA in CDH1 high
(CDH1H) and low (CDH1L) expressing cells suggests distinct
roles for these noncoding transcripts in gene regulation.
The presence of AS-paRNA might have a permissive role in
transcriptional initiation and elongation23,27. Conversely,
the prevalence of S-paRNA in CDH1L cells suggests that this
transcript could contribute to gene silencing. To verify this
hypothesis, we used small interfering RNAs (siRNAs) to target
the S-paRNA and examine the effect on CDH1 transcription.
Promoter-directed siRNAs have been shown to induce
transcriptional repression or activation by diverse mechanisms
depending on promoter architecture and transcriptional state of
genes28–30. Using Sfold we selected siRNAs that target accessible
regions in the S-paRNA and exhibit greater strand-speciﬁcity,
based on differential stability of siRNA duplex ends (DSSE
41 kcalmol 1). Si217 ranked at the top, based on these criteria,
among siRNAs targeting the S-paRNA. Transfection of si217
reactivates CDH1 expression in PC3 and DU145 cells, but had
no effect in LNCaP cells (Fig. 2a). Additional siRNAs (si304 and
si63) directed to distinct non-overlapping sites also reactivate
CDH1 transcription, although less effectively than si217
(Supplementary Fig. 3a,b). Re-expression of CDH1 involves
AGO2 (Supplementary Fig. 3c) and was associated with depletion
of S-paRNA (Fig. 2b and Supplementary Fig. 3d), suggesting that
siRNA-loaded AGO2 interacts with and degrades the S-paRNA to
activate CDH1 transcription. To conﬁrm the strand-speciﬁcity of
si217 we examined the effect in LNCaP cells, which express
almost exclusively AS-paRNA. CDH1 mRNA and paRNA levels
were not affected by the S-paRNA targeting si217 (Supplementary
Fig. 3e).
To assess the dynamic relationship between paRNAs and
CDH1 transcription, we monitored both mRNA and paRNA
levels at different times after siRNA transfection. Depletion
of S-paRNA is followed by increased CDH1 mRNA expression
at 48–72 h (Fig. 2c). This occurs concomitantly with an increase
of total paRNAs and, speciﬁcally, AS-paRNA as documented
by qRT–PCR and strand-speciﬁc RT–PCR (Fig. 2c, middle and
bottom panels), leading to an inversion of the AS/S-paRNA ratio.
At the latest time point, reduced CDH1 mRNA levels coincide
with decreased paRNA and the disappearance of AS-paRNA.
Thus, the level and the balance between S and AS-paRNA dictate
the status of the CDH1 promoter. Furthermore, transient
depletion of S-paRNA triggers transcriptional reactivation in
CDH1L cells.
To gain additional insights on the mode of action of the
S-paRNA, we turned to the CDH1 promoter reporter construct.
We ﬁnd that si217 increases promoter reporter activity, as
observed with the native promoter (Fig. 2d). Moreover, insertion
of a transcription termination site (TS) downstream of the S-TSS
prevents synthesis of full length S-paRNA (Supplementary
Fig. 3f) and increases promoter reporter activity (Fig. 2e).
Conversely, ectopic expression of S and AS-paRNA has no effect
on promoter reporter activity and CDH1 mRNA, indicating that
the promoter-proximal transcripts do not have trans-acting
effects (Supplementary Fig. 3g). Altogether, these results support
the notion that S-paRNA acts locally at the CDH1 promoter and
regulates E-cadherin transcription in cis.
Sense promoter-associated RNA affects cancer cell phenotype.
Our results show the S-paRNA has a central role in maintaining
the silenced state of CDH1 in prostate cancer cell lines: depletion
of the S paRNA re-activates E-cadherin expression in CDH1L
cancer cells. Given the importance of E-cadherin silencing
for epithelial cancers18, we addressed whether preventing
S-paRNA mediated repression reverts the tumorigenic
phenotype. Restoring E-cadherin expression by various means
is known to induce growth arrest and impair tumorigenicity of
cancer cells31–33. We ﬁnd that transfection of si217 inhibits
proliferation of PC3 and DU145 cells, but has no effect in
CDH1H LNCaP cells (Fig. 2f). si63 and si304 had similar effects
on proliferation of PC3 cells (Supplementary Fig. 3h).
Clonogenicity of CDH1L cells is also severely impaired by
si217, giving rise to small clusters of scattered cells compared
to the large colonies formed by control cells (Fig. 2g).
Transfection with si217 also reduces the ability of PC3 and
DU145 cells to form tumour spheres, a feature of CSCs (Fig. 2h).
Reduced tumour sphere formation in vitro correlates with
impaired tumour-initiating and stem-like capability in vivo24,34.
Thus, targeting the S-paRNA reverts the tumorigenic and
stem-like phenotype concomitant with reactivation of CDH1
expression. Altogether, these results conﬁrm the pivotal role of
the S-paRNA in sustaining E-cadherin silencing and the
malignant phenotype.
Sense promoter-associated RNA recruits AGO1 and SUV39H1.
To uncover the mechanism by which S-paRNA modulates CDH1
transcription, we sought to identify additional components of this
regulatory network. We focused on AGO proteins, which are
implicated in transcriptional gene regulation35,36. We ﬁnd that
knockdown of AGO1 increases CDH1 expression (Fig. 3a), while
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depletion of other AGOs has no effect (Supplementary Fig. 4a,b).
AGO1 knockdown also increases CDH1 expression in DU145
cells, but no changes are observed in LNCaP and normal PrECs
(Fig. 3b). We hypothesized that AGO1 could target the CDH1
promoter by interacting with the S-paRNA. We found AGO1 in
the nucleus (Supplementary Fig. 4c) and bound to the CDH1
promoter in PC3 cells in the region overlapping the S-paRNA
(Fig. 3c). Furthermore, RNA-chromatin immunoprecipitation
(RNA-ChIP) show that chromatin-associated AGO1 binds to
S-paRNA, a result consistent with the hypothesis that S-paRNA
guides AGO1 to the promoter (Fig. 3d). This ﬁnding was
conﬁrmed by RNA-immunoprecipitation (RIP) in HA-AGO1
expressing PC3 cells (Supplementary Fig. 4d). Binding of AGO1
to S-paRNA is also observed in DU145 cells, but not in LNCaP
cells (Supplementary Fig. 4e), which do not express the
S-transcript. Thus, the interaction of AGO1 with S-paRNA
occurs in CDH1L cells concomitantly with silencing of the gene.
Consistent with a repressive function, expression of HA-AGO1
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reduces the activity of the CDH1 promoter reporter in PC3 cells,
whereas it is ineffective in LNCaP cells lacking S-paRNA
(Supplementary Fig. 4f). Furthermore, blocking synthesis of
S-paRNA in the promoter reporter by the TS insertion reduces
binding of AGO1, conﬁrming that the S-transcript is required for
AGO1 interaction with the promoter (Supplementary Fig. 4g).
We examined further the interaction of AGO1 with S-paRNA
using RIP and paRNA expression constructs. AGO1 binds
exclusively to the S and not to the AS-transcript, indicating that
the binding is strand and sequence speciﬁc (Fig. 3e). Importantly,
this experiment reveals that AGO1 binds directly to the S-paRNA
independently of promoter DNA. Analysis of S-paRNA deletion
mutants identify the 30 portion of the transcript as the minimal
region required for AGO1 binding, further arguing for selective
sequence-speciﬁc interaction (Fig. 3f). Interestingly, AGO1 is
unable to bind ectopically expressed S- and AS-paRNA in LNCaP
cells (Supplementary Fig. 4h), indicating that formation of the
S-paRNA-AGO1 complex is cell-context dependent and requires
additional cell-speciﬁc elements.
To determine whether AGO1 and S-paRNA inﬂuence the
chromatin state at the CDH1 promoter, we examined the
distribution of activating (H3Ac) and repressive (H3K9me,
H3K27me) histone marks after their knockdown in PC3 cells.
Consistent with a switch to an active state, knockdown of
S-paRNA and AGO1 increases H3Ac and decreases H3K9me at
the CDH1 promoter (Fig. 3g). Notably, the restoration of an
active chromatin environment for the CDH1 promoter after
AGO1 knockdown is also associated with increased AS-paRNA,
as seen after S-paRNA depletion (Supplementary Fig. 4i).
The selective decline of H3K9me, without changes in
H3K27me, after S-paRNA and AGO1 knockdown suggests the
speciﬁc involvement of a H3K9 histone methyltransferase
(HMT), like SUV39H1 or G9a. We showed previously that
knockdown of SUV39H1 reactivates CDH1 expression whereas
G9a knockdown had no effect37. Consistent with this past result,
knockdown of SUV39H1 reduces the levels of H3K9me at the
CDH1 promoter and increases CDH1 expression in PC3 cells
(Supplementary Fig. 4j–l). Treatment with chaetocin, a selective
SUV39H1 inhibitor, similarly reactivates CDH1 transcription
(Supplementary Fig. 4m). Consistent with a link with paRNA,
knockdown of either S-paRNA or AGO1 reduces the amount of
SUV39H1 bound to the CDH1 promoter (Fig. 3h). Furthermore,
we found that SUV39H1 binds to ectopically expressed S-paRNA
in the presence of AGO1 (Supplementary Fig. 4n). These ﬁndings
suggest that AGO1 promotes the interaction of SUV39H1 with
S-paRNA and facilitates its subsequent recruitment to the CDH1
promoter. In turn, SUV39H1 recruited by the S-paRNA-AGO1
complex catalyses H3K9me and silencing of the gene.
A microRNA guides AGO1 to sense promoter-associated RNA.
The formation of the AGO1/S-paRNA complex is a critical step
determining the transition from transcriptional activation to
repression in CDH1L cells. AGO proteins are guided to
their RNA targets by miRNAs35,36. To identify small RNAs
bound to the S-paRNA-AGO1 complex, we combined RIP with
biotin-labelled RNA pull-down (Fig. 4a). Control experiments
with IgG and monitoring the recovery of biotin-labelled S-paRNA
conﬁrmed the efﬁciency and stringency of the procedure. Cloning
and sequencing of the small RNA fraction retrieved a single
prominent small RNA in B70% of the sequenced
clones, indicating a highly speciﬁc interaction with the
S-paRNA-AGO1 complex (Fig. 4b).
The retrieved small RNA has close similarity with human
miR-4534 in miRBase. The two sequences are identical apart
from two nucleotide changes (A to C and G to C) and a single-
base deletion at the 50-end. Public small RNA-Seq databases
contain numerous instances of small RNAs, frequently more
abundant than the canonical miR-4534, with identical or similar
sequences to the cloned small RNA and classiﬁed as isomiRs of
miR-4534 (Supplementary Fig. 5a), suggesting that the AGO1-
bound small RNA could be an isomiR of this miRNA. Using
selective primers, we detected both the mature miR-4534 and the
isomiR-4534 in normal and prostate cancer cell lines (Fig. 4c).
IsomiR-4534 is more abundant than miR-4534 in all cell lines
tested and its expression is lower in normal PrECs compared to
transformed and tumorigenic cell lines. Furthermore, unlike miR-
4534, isomiR-4534 is more abundant in nuclei than in cytoplasm
of PC3 cells (Fig. 4d).
IsomiRs can be produced by mutations or RNA editing38.
Sequencing of the pre-miR-4534 locus did not reveal
any mutation (Supplementary Fig. 5b), thereby favouring
the hypothesis of RNA editing. Interestingly, both canonical
(A-to-I) and non-canonical editing of mRNAs and miRNAs
has been shown in human cells39–42. Therefore, we examined
whether isomiR-4534 could be generated from pre-miRNA-4534.
After transfection of pre-miR-4534, we detect a signiﬁcant
increase of miR-4534 and isomiR-4534, consistent with the
substantial conversion of pre-miR-4534 to both mature miRNAs
(Fig. 4e). Next, we tested the effects of pri-miR-4534 knockdown
on isomiR-4534 levels. To this end, we identiﬁed the primary
transcript of pri-miR-4534 by scanning the region immediately
upstream of the pre-miR-4534 locus on chromosome 22 and
designed a pri-miR-4534-targeting siRNA, which effectively
reduced its level (Supplementary Fig. 5c–e). Knockdown of
pri-miR-4534 reduces both miR-4534 and isomiR-4534
indicating that both mature miRNAs originate from the same
primary transcript, while unrelated miRNAs, miR-21 and
miR-22, were not signiﬁcantly affected (Fig. 4f). In addition,
we used the CRISPR-Cas9-FokI nuclease system43,44 to
genetically modify the pre-miR-4534 locus and prevent
production of the mature miRNA. Transfection with the
pre-miR-4534 targeting vectors (del91-55 and del88-52)
signiﬁcantly reduces the level of isomiR-4534 compared to
control vector transfected cells (Fig. 4g). Single-cell clones
derived from cells expressing the pre-miR-4534 targeting
constructs show deletions in the pri-miR-4534 locus compatible
with single allele inactivation and substantial reduction
of isomiR-4534 (Supplementary Fig. 5f,g). Thus, targeting
pri/pre-miR-4534 using both siRNA and CRISPR-Cas9 leads to
a signiﬁcant reduction of isomiR-4534. Importantly, transfection
of isomiR-4534 reduces CDH1 expression in PC3 cells whereas
miR-4534 has no effect (Fig. 4h). Both isomiR-4534 and
miR-4534 were ineffective in LNCaP cells. Furthermore,
knockdown of pri-miR-4534, which reduces isomiR-4534 level,
increased CDH1 expression in PC3 cells (Fig. 4i).
Collectively, these results support the hypothesis that
isomiR-4534, generated by non-canonical editing of
pri/pre-miR-4534, guides the formation of a repressive complex
on the CDH1 promoter. qRT–PCR after RIP and biotin-labelled
RNA pull-down showed the selective association of isomiR-4534
with the AGO1/S paRNA complex (Fig. 5a). In cells expressing
HA-AGO1, we detect avid binding of isomiR-4534 to AGO1
by RIP (Fig. 5b). Binding of isomiR-4534 is slightly increased by
co-expression of the S-paRNA, while minimal amounts of
miR-4534 are associated with AGO1. Moreover, RNA-ChIP
demonstrates that isomiR-4534 is associated with endogenous
chromatin-bound AGO1 in PC3 cells (Fig. 5c), a result consistent
with the formation of a complex between the miRNA-loaded
AGO1 and S-paRNA on the CDH1 promoter.
To determine how isomiR-4534 guides AGO1 to the S-paRNA,
we interrogated the sequence of the noncoding transcript using
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miRNA target prediction tools. We identify a single potential
target site located at  118 to  134 in the S-paRNA compatible
with miRNA binding45. A shift in the miRNA seed region
allows extended base pairing (8 bp) and the formation of
a stable complex with S-paRNA (DG¼  27.2 kcalmol 1;
Fig. 5d). Conversely, this site is poorly compatible with the
sequence of mature miR-4534, which exhibit incomplete base
pairing in the seed region and a predicted lower afﬁnity
(DG¼  22.8 kcal mol 1) (Supplementary Fig. 6a), suggesting
that editing modiﬁes substantially the seed region and may direct
isomiR-4534 to a distinct repertoire of targets compared to miR-
4534. Consistent with this notion, we ﬁnd a greatly reduced
number of predicted targets of isomiR-4534 in canonical 30-UTR
compared to miR-4534 (Supplementary Fig. 6b).
The predicted isomiR-4534 binding sequence is within the
AGO1 interacting region of the S-paRNA. Mutations in the
isomiR-4534 binding site (BS) reduces AGO1 binding to
S-paRNA, demonstrating that the site anchors AGO1 to the
transcript (Fig. 5e). Furthermore, BS mutations increase reporter
activity compared to the WT reporter (Supplementary Fig. 6c).
Interestingly, the BS mutations did not affect reporter activity
when introduced in the TS reporter unable to synthesize full
length S-paRNA, indicating that the mutations affect primarily
the S-transcript ability to bind AGO1 (Supplementary Fig. 6d).
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Figure 4 | IsomiR-4534 binds to Argonaute 1 and controls CDH1 expression. (a) Protocol for miRNA identiﬁcation by RIP, biotin-labelled RNA pull-down
and small RNA sequencing. (b) Sequence of miR-4534 and isomiR-4534. Red, nucleotide changed in isomiR-4534. (c) miR-4534 and isomiR-4534
expression in prostate normal (PrECs), tumorigenic (ESE3kd-PrECs) and cancer cell lines (LNCaP, DU145 and PC3). (d) Nuclear and cytoplasmic
distribution of miR-4534 and isomiR-4534 in PC3 cells. (e) miR-4534 and isomiR-4534 expression in DU145 cells 24 h after transfection with
pre-miR-4534 (pMIR4534) or control expression vector. (f) Expression of miR-4534, isomiR-4534, miR-21 and miR-22 in PC3 cells after transfection of
pri-miR-4534 targeting (siprimiR) or control (siGL3) siRNA. (g) miR-4534 and isomiR-4534 expression in DU145 cells transfected with pre-miR-4534
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cells after transfection with miR4534 and isomiR-4534 mimics or negative control (ctrl neg) miRNA. (i) CDH1 mRNA (top) and protein (bottom)
expression in DU145 cells transfected with pri-miR-4534 targeting siRNA (siprimiR) or siGL3. Data are mean±s.d. of three independent determinations.
Student’s t-test was used for P value assessment. *Po0.05.
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SNP rs16260 inﬂuences AGO1 recruitment to CDH1 promoter.
SNPs linked to cancer predisposition are present at the CDH1
promoter46. We focused on SNP rs16260 ( 160C4A) located
near the isomir-4534 binding sequence (Fig. 6a). The minor A allele
has been associated with increased risk of epithelial cancers,
including prostate cancer46–48. Furthermore, we found that the A/A
genotype is associated with reduced recurrence-free survival after
prostatectomy in prostate cancer patients (Po0.05; Supplementary
Fig. 7a,b), consistent with an impact on CDH1 expression during
tumour progression. This SNP has been proposed to affect the
binding of unidentiﬁed transcription factors to the CDH1 promoter,
but no direct evidence was provided49.
To investigate whether SNP rs16260 inﬂuenced CDH1
promoter activity, we generated reporter constructs with the
two allelic variants. The  160A reporter exhibits lower
transcriptional activity than the  160C reporter in PC3 cells
(Supplementary Fig. 7c). No difference is observed in LNCaP
cells, consistent with a cell context-dependent effect of the SNP
requiring expression of the S-paRNA. Notably, similar amounts
of sense transcripts are produced from the A and C reporters
(Supplementary Fig. 7d). Intriguingly, we did not ﬁnd a clear
correlation between the rs16260 genotype and CDH1 expression
in cell lines, conﬁrming that the SNP’s effect are manifest only in
a speciﬁc context (Supplementary Fig. 7e).
Based on the proximity to the isomiR-4534 binding sequence,
we hypothesized that SNP rs16260 could affect the interaction of
AGO1 with the CDH1 promoter. Therefore, we performed RIP
with the two S-paRNA allelic variants. AGO1 binds preferentially
to the  160A allele (Fig. 6b), also leading to preferential binding
of SUV39H1 to ( 160A)S-paRNA in the presence of AGO1
(Supplementary Fig. 7f). Importantly, the effect of the SNP
depends on the presence of the S-paRNA and are completely
independent of promoter DNA.
Using allele-speciﬁc RNA-ChIP qPCR in the heterozygous
DU145 cells we ﬁnd that SNP rs16260 has a similar impact on
the association of chromatin-bound AGO1 to the CDH1
promoter (Fig. 6c). AGO1 binds almost exclusively to
( 160A)S-paRNA with minimal binding to the  160C allele.
Consistent with this result, allele-speciﬁc ChIP qPCR showed
preferential binding of AGO1 to the promoter carrying the
 160A allele (Fig. 6d). Thus, SNP rs16260 affects the ability of
S-paRNA to bind and recruit AGO1 to the CDH1 promoter.
Based on sequencing data, similar amounts of  160A and
 160C transcripts are produced in heterozygous DU145 cells
(Supplementary Fig. 7g), thus excluding unbalanced synthesis
from the two alleles as the cause of the preferential binding of
AGO1 and arguing in favour of a qualitative difference between
the two allelic variants.
Since SNP rs16260 does not alter the isomiR-4534 binding
sequence, we hypothesized that the polymorphic site could
inﬂuence the assembly of the S-paRNA-AGO1 complex indirectly
by altering the transcript secondary structure. Using Mfold, a
RNA structure prediction tool, we determined that the minimal
AGO1 binding region ( 281/ 57) of S-transcript folds in a
well-deﬁned secondary structure, which is also maintained in the
full length ( 668/ 57) S-paRNA (Supplementary Fig. 8a,b).
Interestingly, SNP rs16260 introduces conformational changes,
which are limited to the AGO1 binding region and affect
the organization of three main stem-loops, one of them
encompassing the isomiR-4534 binding site. Analysis of base-pair
probability performed with Sfold indicates differences at the
isomiR-4534 binding site between the two allelic variants
(Supplementary Fig. 8c). We further compared between the two
allelic variants the free energy requirement for forcing the
hairpin ( 138 to  117 nt) including the isomiR-4534
binding site into single-strand conformation and to make it
accessible (Supplementary Fig. 9a,b). Unwinding of the hairpin
in the ( 160A)S-paRNA was signiﬁcantly facilitated compared
to  160C allele (DDG¼  9.31 versus  13.33 kcal mol 1)
(Supplementary Fig. 9c).
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The secondary structure of the full length S paRNA
( 688/ 57) with either A or C variants was then
experimentally determined using selective 20-hydroxyl acylation
and primer extension (SHAPE)50. Consistent with the in silico
predictions, SHAPE reveals that the S-paRNA is highly
structured, including the region near SNP rs16260 (Fig. 7a).
The isomiR-4534 binding sequence is partially double-stranded as
well, suggesting that access of the AGO1/isomiR-4534 complex is
affected by the RNA secondary structure. Furthermore, the A and
C variants differ signiﬁcantly in the pattern of SHAPE reactivity
at and around SNP rs16260, revealing a change in the secondary
and tertiary structure of the transcript for the two polymorphic
sequences (Fig. 7a). Using RNAstructure we generated secondary
structure models that were consistent with the SHAPE data and
differed signiﬁcantly between the two variants (Fig. 7b,c). The
 160A allele paRNA has increased spacing between loop L1 and
the isomiR-4534 -binding site hairpin, which at visual inspection
could allow better access to the AGO1-isomiR-4534 complex
compared to the  160C allele.
Using the SHAPE-determined structures to estimate the
likelihood of the isomiR-paRNA interaction, we ﬁnd that the C
to A exchange at position  160 decreases the base-pairing
probability for the isomiR-4534 binding site hairpin from 499%
to 90–95%, indicating a greater predisposition of the hairpin to
unwind and allow access to the isomiR-4534 by strand invasion
(Supplementary Fig. 10). The target accessibility and binding
energy for the isomiR-4534-paRNA interaction were further
estimated using RNAup. Consistently, the energy requirements
for both unwinding of the target (9.6 versus 12.0 kcal mol 1) and
isomiR-4534 binding ( 7.8 versus  5.4 kcal mol 1) indicate
greater accessibility and binding capacity of the  160A allele
(Supplementary Fig. 11). The greater accessibility of the
( 160A)S-paRNA to isomiR-4534 would in turn increase its
ability to recruit AGO1.
To test directly this hypothesis, we restored the stem-loop
conformation observed for the  160C allele by introducing in
the ( 160A)S-paRNA a single compensatory mutation (G141U)
to recreate the base pairing (C160:G141) at the base of the hairpin
disrupted in the A variant (A160/G141) (Fig. 7b,c). The G141U
mutant allows the base pairing (A160:U141) and establishes a
stem-loop structure as observed for the  160C variant
(Supplementary Fig. 12). When the G141U mutation is
introduced in the ( 160A)S-paRNA, binding of AGO1 is
substantially reduced, conﬁrming that the transcript secondary
structure inﬂuences isomiR-4534 access and AGO1 binding
(Fig. 7d). Thus, the structural change induced by the  160A
allele favours unwinding of the stem-loop and assembly of the
isomiR-4534-AGO1complex on the S-paRNA compared to the
 160C allele.
Discussion
This study investigates how promoter-proximal transcripts
sustain transcriptional silencing of E-cadherin in cancer cells.
Furthermore, the analysis of a cancer-associated genetic
polymorphism in the CDH1 promoter uncovers a mechanism
by which noncoding genetic variants inﬂuence epigenetic
processes and affect functional elements in promoter–proximal
transcripts by altering RNA secondary structure.
Epigenetic silencing of tumour suppressor genes like CDH1 are
key events in tumour development and progression51. Here, we
show that transcriptional silencing and activation of CDH1 are at
least partially controlled by an epigenetic switch that relies on S
and AS-transcripts generated from distinct initiation sites
upstream of the gene TSS (Fig. 8). The transition from the
active to the inactive state of the CDH1 promoter is associated
both in cell lines and human tumours with changes in the relative
abundance of S and AS-paRNAs. Mechanistically, the S-paRNA,
which is chromatin-bound and present at very low copy number,
cooperates with AGO1 to recruit SUV39H1 to promote a
repressive chromatin state. Knock-down of either S-paRNA or
AGO1 impairs the binding of SUV39H1 and reactivates CDH1
transcription. Thus, S-paRNA and AGO1 coordinate the access to
the promoter of SUV39H1 and possibly other regulatory factors
that maintain the repressive state. S and AS-paRNAs are
substantially non poly-adenylated, accumulate in nuclei and
remain attached to chromatin. Notably, these transcripts
originate from distinct and functionally independent initiation
sites upstream of the gene TSS which, when inserted in a
promoter-less reporter as well as in the context of full length
promoter constructs, exhibit striking cell context speciﬁcity and
directionality, a set of observations consistent with other recent
studies of upstream promoter transcripts25,26,52.
Both AGO1 and AGO2 are present in nuclei of mammalian
cells and interact with chromatin modiﬁers, components of the
splicing machinery and gene promoters53–55. Here, we show
that AGO1 binds to the CDH1 promoter and is guided by a
miRNA (isomiR-4534) to a speciﬁc site on the S-paRNA. This
miRNA-guided AGO1 complex represses promoter activity and
maintains gene silencing. The novel miRNA (isomiR-4534)
identiﬁed in this study is generated by non-canonical editing of
the pri/pre-miR-4534, is abundant in cancer cells compared to
normal epithelial cells and suppresses CDH1 expression when
transfected in S-paRNA expressing cells.
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Figure 6 | SNP rs16260 affects binding of Argonaute 1 to sense
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The paRNA-based epigenetic network in the CDH1 promoter
is inﬂuenced by a genetic polymorphism, SNP rs16260, which
affects the ability of the S-paRNA to form a complex with
miRNA-AGO1 independently of changes in DNA regulatory
elements. The  160A allele is associated with increased risk of
multiple types of cancer, including prostate cancer46–48. We ﬁnd
that the  160A allele increases AGO1 binding in a S-paRNA
dependent manner and reduces CDH1 promoter activity. RNA
secondary structure prediction analyses and SHAPE show
that the AGO1 binding region of the S-paRNA forms three
closely-spaced stem-loops that overlap with the isomiR-4534
binding site. The SNP rs16260 causes a change in S-paRNA
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Figure 7 | SNP rs16260 inﬂuences folding of sense promoter-associated RNA. (a) SHAPE reactivity gel analysis of the sense transcript ( 688/ 57)
showing the region encompassing SNP rs16260 with C (left) and A (right) variants. G, A, and C, sequencing lanes. Samples were incubated with 0
(DMSO), 32 or 65mM NMIA. Yellow boxes, position of the polymorphic site with either C or A variant. (b,c) Secondary structures of S-paRNA with
the  160C (b) and  160A (c) allele built using RNAstructure based on SHAPE-derived constraints and visualized using VARNA. Colours mark
nucleotides that are either unstructured (red, SHAPE Z0.85), well-ordered (black, SHAPE o0.4), with intermediate reactivity (orange) or
non-resolved/undetectable (gray). (d) Binding of HA-AGO1 to  160A and mutated  160A/G141U S-paRNA determined by RIP. B, bulges; dark gray box,
isomiR-4534 binding site; L, loops; light gray boxes, base pair in  160C allele disrupted in  160A variant.
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structure near the  160(C/A) site that extends to the
isomiR-4534 target sequence, resulting in changes in the
relative distance and local folding of the core hairpins.
The structural changes imposed by the SNP  160(C/A) affect
the ability of isomiR-4534 and AGO1 to bind to S-paRNA,
leading to increased binding of AGO1 to the  160A allele. The
increased propensity of the A allelic variant to bind AGO1 would
favour silencing of the gene in permissive cells.
In summary, our ﬁndings provide new insight on the
contribution of paRNAs to the epigenetic machinery and to
the impact of genetic variants on gene expression. An increasing
number of disease-associated SNPs map to long ncRNAs and are
proposed to change their protein binding capability56–59. Our
result suggest that altering the sequence, structure and, therefore,
function of paRNAs provides an additional and still unexplored
way by which polymorphic sites and somatic mutations in
noncoding regions inﬂuence the epigenetic landscape and impact
on human disease. These results also support the development of
inhibitors targeting these ncRNAs for gene-selective
transcriptional reprogramming28,34,60,61, since knockdown of
S-paRNA reactivates CDH1 expression in prostate cancer cells
and impairs their proliferative, clonogenic and stem-likeness.
Reprogramming transcription of individual genes through this
approach would have broad implications for epigenetic therapy of
cancer and other diseases.
Methods
Cell cultures and transfection. Prostate cancer cell lines (PC3, LNCaP and
DU145) were obtained from ATCC and maintained in RPMI-1640 (Gibco)
supplemented with 10% FBS. Cells lines are characterized by DNA proﬁling (short
tandem repeat analysis). Cells were used within 6 months of culturing and regularly
checked for Mycoplasma contamination using the MycoAlert Mycoplasma
Detection Kit (Lonza). Normal (PrEC) and transformed (EHFkd-PrEC)
prostate epithelial cells were previously described24. EHFkd-PrEC cells were
generated by stable transfection of PrEC with ESE3/EHF-directed short hairpin
RNAs (shRNA). Both PrEC and EHFkd-PrEC were maintained in serum-free
complete Prostate Epithelial Growth Medium (PrEGM; Cambrex, Lonza), which is
supplemented with Bovine Pituitary Extract (BPE), hydrocortisone, Human
Epidermal Growth Factor (hEGF), epinephrine, insulin, triiodothyronine,
transferrin, gentamicin/amphotericin-B, and retinoic acid.
siRNAs, including Silencer Negative Control (siControl), were purchased from
Ambion. siRNA sequences are shown in Supplementary Table 1. S-paRNA
targeting siRNAs were selected using Sfold to ensure maximum target accessibility
and strand-speciﬁcity towards the sense transcript, based on the average unpaired
probability of the targeted sequence and asymmetry of the base composition
(differential stability of siRNA duplex ends, DSSE¼41 kcal mol 1). Cells were
transfected with siRNAs using Lipofectamine2000 (Invitrogen) or Interferin
(Polyplus)60. Plasmids were transfected with JetPRIME (Polyplus). To assess the
effects on cell proliferation, colony formation and tumour sphere formation, cells
were transfected with the indicated siRNAs (100 nM) and 24–72 h later detached,
counted and reseeded as previously described34,60. For cell proliferation assays cells
were plated in 12-well plates with four replicates per experimental group. At the
indicated time points viable cell number was determined by trypan blue counting.
For colony assay cells were plated in triplicate in 6-well plates (1,000 cells per well).
After 12–14 days, cells were ﬁxed and stained with 1% crystal violet in 20% ethanol.
Colonies were counted with an automated colony counter (Alphaimager). To assess
tumour sphere formation cells were plated in ultra-low attachment dishes (Corning
Life Sciences) in serum-free Mammary Epithelial Basal Medium (MEBM,
Cambrex). Tumour spheres (Z50mm in diameter) were counted after 8–10 days.
RNA and SNP analysis in tissue samples. Tissue samples were collected with
approval of the Ethical Committee of the Piedmont Region, Italy, and written
informed consent from patients undergone radical prostatectomy for localized
prostate cancer62. Total RNA was extracted from snap frozen tumour samples
(n¼ 24) using SV Total RNA Isolation System (Promega) and analysed by
RT–qPCR or strand-speciﬁc RT–qPCR. Primers (paRNA, CDH1  282F and
 171R; CDH1 mRNA, CDH1 þ 2497F and þ 2619R) are shown in
Supplementary Table 2. For genotyping by restriction fragment length
polymorphism (RFLP) analysis or sequencing, genomic DNA was extracted from
two 10-mm sections of formalin-ﬁxed parafﬁn embedded (FFPE) prostate tumour
specimens (n¼ 47) using DNeasy Tissue and Blood kit (Qiagen). Genomic DNA
was ampliﬁed by PCR along with positive (Male DNA Universal Reference) and
negative control (No template) reactions using primers (CDH1  272F and
 82R). PCR products (5 ml for cell lines and 15ml for FFPE samples) were digested
with HincII (TaKaRa) and analysed by agarose gel electrophoresis. SNP analysis in
cell lines was performed by RFLP and sequencing. The relationship between SNP
rs16260 and recurrence-free survival was examined in a patient cohort with
available pathological and clinical follow up data24.
Promoter-associated transcript prediction. Raw data from global nuclear run-on
sequencing (GRO-Seq) performed in various cell lines were downloaded. Source of
the data were for LNCaP cells (series GSE47805, sample GSM1159895)20, MCF7 cells
(series GSE45822, samples GSM1115995, GSM1115996, GSM1115997 and
GSM1115998)21, HCT116 cells (series GSE53964, samples GSM1304424,
GSM1366021 and GSM1304426)22 and h1ESC cells (series GSE41009, samples
GSM1006729 and GSM1006731)23. The raw reads in fastq ﬁles were extracted and
aligned with bowtie2 (version 2.2.1)63 allowing up to 1 mismatch and accepting
uniquely mapping reads on the reference genome GRCh37.p13 provided by
Genecode. Samtools (version 0.1.19)64 was used to convert sam to bam ﬁles and sort
them. Using HOMER (Hypergeometric Optimization of Motif EnRichment) suite of
tools for Motif Discovery and next-generation sequencing analysis19 we predicted
genome-wide the transcription events for each cell lines (‘ﬁndPeaks.pl’) allowing a
minimum size of 50 bp for transcript body detection. Only transcripts identiﬁed
within 2 kb upstream to TSS of annotated genes were considered as promoter-
proximal transcripts. The predicted promoter-associated transcripts were annotated
as S and AS relative to the direction of the adjacent gene (Supplementary Table 3).
Quantiﬁcation of rpkm values of annotated and novel transcripts was performed with
‘analyzeRepeats.pl’ included in HOMER suite. To visualize GRO-Seq data Integrative
Genomics Viewer (IGV) was used (version 2.3.32).
Cloning and site-directed mutagenesis. pIRESneo-FLAG/HA-AGO1 expression
vectors was obtained from Addgene. pGL3-CDH1 promoter reporter was provided
by Dr H. Crawford and Myc-tagged SUV39H1 was provided by Dr D. Reinberg.
pGL3 basic and pRL-SV40 were obtained from Promega. pcDNA3.1(þ / ) from
Invitrogen. CDH1 promoter fragments were ampliﬁed from pGL3-CDH1
promoter ( 790/þ 48) using AmpliTaq Gold Polymerase (Roche). Promoter
fragments  790/ 709 (S-TSS) and  57/ 280 (AS-TSS) were subcloned in
pGL3-basic using KpnI/HindIII and HindIII/SacI restriction sites, respectively.
Promoter fragment  373/þ 48 was subcloned in pGL3-basic using KpnI and
BglII restriction sites. Promoter fragments  668/ 57,  476/ 57,  668/ 261
and  281/ 57 were cloned into pcDNA3.1(þ / ) plasmid either in sense or
antisense orientation using either EcoRI and ApaI or BamHI and ApaI restrictions
sites. Site-directed mutagenesis was performed with Invitrogen Mutagenesis System
Kit using either pGL3 or pcDNA3.1 vectors as templates. Primers for PCR
ampliﬁcation and site-directed mutagenesis are shown in Supplementary Table 2.
ApaI and EcoRI restriction sites were introduced by site-directed mutagenesis at
position  668 of the pGL3-CDH1 promoter to produce the pGL3-CDH1-T1
promoter vector. To generate the pGL3-CDH1-TS promoter vector the tran-
scription termination sequence (SV40 polyA site) in the pGL3-basic plasmid was
PCR ampliﬁed and cloned in the ApaI-EcoRI sites of pGL3-CDH1-T1 promoter
vector. Plasmids were ampliﬁed in JM109 or DH5a competent cells and puriﬁed by
GenElute Plasmid Miniprep Kit (Sigma). DNA sequences of all constructs were
conﬁrmed by DNA sequencing.
Luciferase reporter assay. Luciferase promoter reporter vectors (100–200 ng)
were transfected along with pRL-SV40 Renilla luciferase reporter (10 ng) in cells
plated in 48-well plates. After 48 h Fireﬂy and Renilla luciferase activities were
measured using Dual Luciferase assay kit (Promega). Renilla luciferase was used to
normalize for transfection efﬁciency.
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Figure 8 | Proposed model of the impact of SNP rs16260 on CDH1
promoter regulation. Assembly of the isomiR-4534/AGO1 complex on
sense promoter-associated RNA silences CDH1 transcription. SNP rs16260
inﬂuences, through changes in the sense transcript secondary structure, the
loading of isomiR-4534/AGO1 and the assembly of the transcriptional
silencing complex.
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RNA extraction. Total RNA was extracted from cell lines using SV Total RNA
Isolation System (Promega). RNA samples were treated with DNase I (Promega)
to remove genomic DNA. For miRNA expression analysis RNA was puriﬁed
by phenol-chloroform extraction. To examine intracellular distribution of
promoter-associated transcripts cells were lysed in 100mM Tris HCl (pH 7.4),
100mM NaCl, 2.5mM MgCl2, 40mgml 1 Digitonin (RSB-100)65. After
centrifugation the supernatant containing cytosolic RNA was collected. Pellets were
suspended in RSB-100 with 0.5% Triton X (RSB-100T) and after centrifugation the
supernatant containing nuclear RNA was recovered. The ﬁnal pellets were
suspended in RSB-100T, sonicated and centrifuged. The supernatant containing
chromatin-bound RNA was recovered. RNA was extracted from all the collected
fractions using TriReagent (Invitrogen).
50 and 30 rapid ampliﬁcation of cDNA ends. 50 RACE was performed with
gene-speciﬁc primers for the sense and antisense transcripts (Supplementary
Table 2) using Invitrogen 50 RACE System and RNA from PC3 and LNCaP cells.
cDNA was puriﬁed, tailed with dCTP and ampliﬁed consecutively with gene
speciﬁc primers and either Abridged Anchor primer or Abridged Universal
Ampliﬁcation primer provided in the 50RACE system kit. For 30RACE, nuclear and
chromatin-associated RNA was polyadenylated with Poly(A) tailing kit (Applied
Biosystem). Polyadenylated RNA was then retro-transcribed and ampliﬁed
consecutively with gene-speciﬁc primers using Invitrogen 30 RACE system kit.
Final PCR products were cloned into pGEM-T Easy vector (Promega) and
sequenced.
Polymerase chain reaction. RT–PCR was performed using SuperScript One Step
RT-PCR system (Invitrogen). Samples were analysed by agarose gel electrophoresis
followed by staining with GelRed (Biotium) and imaging with AlphaImager
(Innotech) with primers (paRNA, CDH1  303F and  153R; CDH1 mRNA,
CDH1 þ 610F and þ 810R) (Supplementary Table 2). Densitometry was
performed using the AlphaImager software. Uncropped images of the gels are
shown in Supplementary Figs 13–17. For strand-speciﬁc RT-PCR either the
forward or reverse primers were added separately to the reverse transcriptase
reaction. Both for RT-PCR and strand-speciﬁc RT-PCR, reactions in which the
reverse transcriptase step, PCR primers or template RNA were omitted were run in
parallel to exclude presence of genomic DNA and self-priming. To conﬁrm speciﬁc
RNA ampliﬁcation, DNase-treated RNA extracted from cells transfected with
expression vectors was incubated with or without RNase A (1 mg, USB) for 10min
at 37 C and before RT-PCR. Quantitative RT-PCR (qRT-PCR) was performed
using EXPRESS-One step SYBR GreenER (Invitrogen) on ABI Step One Plus
(Applied Biosystems) and primers for paRNA (CDH1  303F and  153R) and
CDH1 mRNA (CDH1 þ 2,497F and þ 2,619R). Strand-speciﬁc qRT-PCR was
performed using Power SYBR Green One-step RNA-to-Ct system (Invitrogen)
using either forward or reverse primers in the reverse transcriptase step. qRT–PCR
data were analysed using standard curves and normalized to b-actin as reference
gene. Quantitative real-time PCR (qPCR) using genomic DNA as template was
performed using SYBR Green FAST qPCR (KAPA Biosystem).
Allele-speciﬁc qPCR. Allele-speciﬁc qPCR was performed using SYBR FAST
qPCR (KAPA biosystem) and allele-speciﬁc primers (CDH1  180_AF,  180_CF
and  57R) (Supplementary Table 2). Forward primers contained an internal
mismatch adjacent to the nucleotide complementary to the polymorphic site as this
was shown to increase allele discrimination66. To increase sensitivity a ﬁrst round
of PCR or RT-PCR using DNA or RNA template was performed with primers
ﬂanking the site of interest (CDH1  476F and  57R). Samples were then diluted
and ampliﬁed with internal allele-speciﬁc primers. Conditions for allele-speciﬁc
qPCR were determined by testing serial dilutions of ﬁrst round PCR products and
genomic DNA from homozygous and heterozygous cells to ensure efﬁciency and
selectivity of the method. Data were analysed using the standard curve method.
MicroRNA quantiﬁcation. Total RNA was retro-transcribed using TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystem). The resulting cDNA
was used as template to measure miR-4534, miR21 and U6 snRNA using
pre-designed TaqMan Small RNA Assays and a custom made TaqMan assay for
isomiR-4534 (Applied Biosystem). Data were analysed using either the DDCt or
standard curve method as indicated.
DNA and RNA sequencing. DNA or RNA was ampliﬁed by PCR or directional
RT–PCR, respectively, with the indicated primers for the CDH1 and paRNA
(CDH1  281F,  139R) and pre-miR-4534 (pre-miR  194F, þ 99R)
(Supplementary Table 2). After gel electrophoresis, PCR products were puriﬁed
using Qiaquick PCR puriﬁcation system (Qiagen) and sequenced.
Immunoblotting. Cells were lysed in 2.5% SDS and 250mM Tris-HCl, pH 7.4, at
95 C. For cell fractionation experiments cells were collected using NE-PER Kit
(Pierce) and fractions collected according to manufacturer’s instructions. Gel
electrophoresis and immunoblotting were done as described24. Protein samples
were quantiﬁed using BCA Protein Assay Kit (Pierce) and 40 mg of protein we
loaded in 10%-12% polyacrylamide-SDS gels for electrophoresis. Proteins were
then transferred to nitrocellulose membranes for immunoblotting. Membranes
were blocked for 1 h with I-block (Applied Biosystem) and then probed overnight
at 4 C with the indicated antibody. Immunoblots were developed using antibodies
directed to E-cadherin (BD Biosciences, 610182,1:5,000), b-tubulin (Santa Cruz,
sc5236, 1:2,000), GAPDH (Millipore, MAB374, 1:2,000) and anti-mouse
(Amersham, NA931-1ML, 1:10,000) or anti-rabbit (Amersham, NA934-1ML,
1:20,000) secondary antibodies. The antibody directed to AGO1 (1:400) was
provided by Dr M. Siomi67. Uncropped images of the blots are shown in
Supplementary Figs 13–17.
Chromatin immunoprecipitation. Chromatin was prepared and processed as
described60. Brieﬂy, cells in complete RPMI with 10% FBS were exposed to 1%
formaldehyde for 10min. Cells were then washed and lysed in SDS lysis buffer
(5 106 cells per ml). Cell lysates were sonicated to shear chromatin and obtain
DNA fragments in the range of 200–500 bp. After sonication, the supernatants
containing the shared chromatin were recovered by centrifugation and divided in
50-ml aliquots each with 5 105 cell equivalents. Each 50-ml aliquot was diluted in
a ﬁnal volume of 500 ml of dilution buffer containing 20 ml of protein A magnetic
beads (Upstate). Before the addition of the beads, 10% of each diluted chromatin
sample was preserved as Input. Each sample aliquot was incubated overnight at
4 C with the appropriate antibody. Antibodies for histone H3 dimethylated lysine
9 (H3K9me2, 07–441 EMD Millipore, 8 mg), histone H3 trimethylated lysine 27
(H3K27me3, 07–449 EMD Millipore 5 mg), acetylated histone H3 (H3Ac, 06–599
EMD Millipore, 5 mg), SUV39H1 (Millipore, 05–615, 5 mg) and AGO1 (Merck
Millipore, 03–249, 5 mg), and anti-HA (Santa Cruz, F7 SC-7392, 5 mg) were used for
immunoprecipitation.
Immunoprecipitates were washed four times using a magnetic separator. After
the last wash, both immunoprecipitates and input samples were suspended in
100 ml of elution buffer containing 200mM NaCl and incubated at 65 C for 4 h to
reverse crosslinking. Next, 4 ml of 1M Tris-Cl, pH 6.5, 2 ml of 0.5M EDTA and 1 mg
of Proteinase K were added to the samples which were then incubated at 42 C for
45min. Magnetic beads were removed and DNA was puriﬁed using QIAquick PCR
puriﬁcation KIT (Qiagen). qPCR (primers CDH1  281F and  139R) was
performed as described above. The amount of input and immunoprecipitated DNA
was calculated in reference to standard curves. Data are presented as fraction of
immunoprecipitated DNA relative to the amount of input DNA in each sample.
RNA immunoprecipitation. Cells transiently transfected with HA-AGO1,
Myc-SUV39H1 and/or paRNA expression vectors were collected after 48 h and
processed using Magna RIP RNA Binding Protein Immunoprecipitation Kit
(Millipore). Samples were incubated overnight with Magnetic Beads Protein A/G
coupled with antibodies directed to HA-tag (F7, Santa Cruz, F7 SC-7392, 5 mg) or
Myc (Santa Cruz, A14 SC-789, 5 mg). Beads were washed and RNA was extracted
using SV Total RNA Isolation System (Promega). An additional step of DNase I
digestion (Qiagen) was performed to remove any plasmid or genomic DNA.
Samples were analysed by end-point or quantitative RT–PCR as described above.
CD44 mRNA, an AGO1-bound transcript54, was used as positive control in RIP
experiments with transiently transfected cells. To examine the association of
endogenous AGO1 to the CDH1 promoter by RIP, nuclei were isolated from
non-transfected cells using NE-PER Kit (Pierce) and then processed using Magna
RIP kit and Magnetic Beads Protein A/G (Millipore) coupled with anti-AGO1
(RIPAbþ Ago1 Antibody, 03–249—EMD Millipore, 5 mg) antibody.
RNA chromatin immunoprecipitation. For RNA-ChIP we followed the ChIP
protocol described above except that RNAseOUT (40U, Invitrogen) was added to
the lysis and binding buffers and DNase I digestion was performed before adding
antibodies. Reversal of cross-linking was reduced to 2 h (ref. 68). Beads were
washed and RNA was extracted and analysed by end point RT–PCR or qRT–PCR
as described above.
Identiﬁcation of small RNAs. Sense promoter-associated RNA was synthesized
by in vitro transcription using T7 RNA Polymerase (Roche) and the pGEM-CDH1
promoter vector ( 668/ 57 fragment) as template. Production of the correct
transcript was veriﬁed by denaturating polyacrylamide gel electrophoresis. In vitro
transcribed RNA (50 nmol) was biotinylated using RNA 30 End Biotinylation Kit
(Pierce) according to manufacturer’s instructions. Biotin-labelled S-paRNA was
puriﬁed by phenol-chloroform extraction followed by DTR desalting columns
(Edge Biosystems) to eliminate free biotin moieties. PC3 cells were transfected with
pIRESneo-FLAG/HA-AGO1 plasmid (2 mg) and 10 pmol of in vitro transcribed
biotin-labelled S-paRNA using Lipofectamine. Control samples included cells
transfected with in vitro transcribed non-biotinylated S-paRNA and an unrelated
control RNA (pcDNA3.1 plasmid) as well as RIP with control IgG. Cells were
collected after 24 h and subjected to RIP as described with minor modiﬁcations69.
Brieﬂy, cells were crosslinked with 1% formaldehyde, washed and lysed in RIP lysis
buffer (Hepes 50mM, EDTA 1mM, Triton-X 1%) containing RNAseOUT (40U,
Invitrogen). Lysates were then sonicated and treated with DNAse in presence of
25mM MgCl2 and 5mM CaCl2. Cell lysates were incubated for 2 h at 4 C with
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15622 ARTICLE
NATURE COMMUNICATIONS | 8:15622 | DOI: 10.1038/ncomms15622 | www.nature.com/naturecommunications 13
5 mg of anti-HA antibody (F7, Santa Cruz, F7 SC-7392) or control IgG and 20 ml of
magnetic beads (Millipore). Magnetic beads (Millipore) were washed and RNA was
eluted in 100mM Tris HCl, pH 7.8, 10mM EDTA, 1% SDS. Samples were diluted
in 10mM Tris HCl, pH 7.5, 1mM EDTA, 100mM NaCl (TEN-100) and incubated
with Streptavidin magnetic beads (Roche) for 30minutes at room temperature.
After washing with 10mM Tris HCl, pH 7.5, 1mM EDTA, 1M NaCl (TEN-1000),
RNA was eluted by heating at 65 C for 10min in 10mM Tris HCl, pH 6.0, 1mM
EDTA, 2M NaCl. Samples were digested with proteinase K for 1 h at 42 C and 1 h
at 65 C. RNA was then extracted using TriReagent. Small RNAs associated with
the AGO1 and S-paRNA complex were puriﬁed and cloned using miRCAT Small
RNA Cloning Kit (Integrated DNA Technologies) according to the manufacturer’s
protocol. A total of 39 clones were sequenced and 9 of 13 clones with inserted
sequences (70%) had the identical sequence that we identiﬁed as isomiR-4534.
Experiments with control IgG and monitoring of recovery of biotin-labelled
S-paRNA conﬁrmed the speciﬁcity and stringency of the procedure. The amount of
biotin-labelled S-paRNA recovered after RIP with control IgG was minimal.
Therefore, cloning and sequencing of the small RNAs fraction in this condition was
unlikely to provide information on the S-paRNA-bound small RNA fraction.
Similarly, RNA pull-down of samples containing non-biotin labelled RNA or
control RNA did not yield detectable amounts of biotin-labelled S-paRNA. To
assess recovery of biotinylated S-paRNA by streptavidin-afﬁnity puriﬁcation an
aliquot of the samples was resuspended in 1M NaCl, 5mM EDTA, 50mM MOPS,
pH 7.4, 2M b-mercaptoethanol, heated for 3minutes at 95 C to detach from
biotin-labelled RNA from streptavidin beads. RNA was extracted with TriReagent
and then RT-PCR was performed to detect S-paRNA.
CRISPR-Cas9-FokI induced mutagenesis. Multiplex gRNA target site
oligonucleotides for miR-4534 locus were designed by Ziﬁt software
(http://ziﬁt.partners.org). Two different couples of targeting oligoduplexes
(pre-miR-4534-91 and pre-miR-4534-55; pre-miR-4534-88 and pre-miR-4534-52)
and a middle ultramer duplex were synthesized (IDT, Integrated DNA
Technologies). Oligomers were cloned in pSQT1313 (Addgene) to produce the
targeting constructs pSQT1313 del-91-55 and pSQT1313 del-88-52. pCAG-hCys4-
T2A-nls-hFokI-dCas9-nls (pSQT1601, Addgene) along with pSQT1313 del91-55,
pSQT1313 del88-52 or empty pSQT1313 (ratio 3:1) were co-transfected in DU145
cells using JetPrime (Polyplus). pEZX-MR04 (Clonetech) was added (1% of total
DNA) to the transfection mix for puromycin resistance. Three days after trans-
fection cells were put under selection (Puromycin, Sigma, 0.5 mgml 1). RNA was
extracted after 2–4 days to assess miRNA expression. Aliquots of transfected cells
were reseeded in 96-well plates to isolate single cell clones by limiting dilution.
Single cell clones that were able to expand were collected and analysed for genomic
indels and miRNA levels. DNA was obtained from a total of 37 clones derived from
cells transfected with FokI-dCas9 and pSQT1313 d91–55 (n¼ 11), pSQT1313
d88-52 (n¼ 18) or pSQT1313empty (n¼ 8). DNA was ampliﬁed with primers for
the miR-4534 locus (MIR4534-328 Fw, MIR4534þ 99 Rev; Supplementary
Table 2). PCR products were puriﬁed using Qiaquick PCR puriﬁcation system
(Qiagen) and sequenced. Chromatograms were analysed by Mutation Surveyor
(Softgenetics) to detect indels and perform trace deconvolution.
MicroRNA and isomiR database search. miRBase (www.mirbase.org) was used
to search for mature miRNAs or premiRNAs (stem loop sequences) with identity
or similarity to the cloned AGO1/S-paRNA associated small RNA using BLASTN
and SSEARCH methods, respectively. Small RNA-seq databases were searched for
miR-4534 and related isomiR sequences. miRGator70 and YM500 (ref. 71) include
deep sequencing data from human samples collected from GEO, SRA and TCGA
archives. Using the provided software we retrieved all isomiRs with up to two
mismatches relative to the genomic sequence of mature miR-4534.
RNA secondary structure and microRNA target prediction. Mfold72 was used
to predict secondary structure of S-paRNA, base-pair probability and the inﬂuence
of rs16260 on local folding structure. Forced and non-forced hairpin structures
(consecutive bases from  138 to  117) were generated using Mfold by
introducing the matrix (P 147 0 16). Accessibility of S-paRNA target region to
isomiR-4534 was examined using RNAup (RNAfold website). The analysis of the
hairpin probability proﬁle (H-plot) of the S-paRNA allelic variants was done using
Sfold. Diana MicroT73 and TargetScan74 were used to identify putative targets of
isomiR-4534 and miR-4534 in 30UTR of mRNAs. RNAhybrid75 and STarMir, an
application module of the Sfold software76, were used to identify potential binding
sequences of isomiR-4534 and miR-4534 in the S-paRNA.
In vitro transcription. pcDNAþ plasmids with  668/ 57 (A or C),
 476/ 57 promoter fragments were linearized with the 50 overhang 30 termi-
nation restriction enzyme PspOMI (New England Biolabs) or, in case of the
 281/ 57, construct ampliﬁed from the plasmid with the set of primers
(SHAPE, pcDNA  120—paRNA F and pcDNA paRNA þ 61 polyA R)
(Supplementary Table 2). Digested plasmids or PCR ampliﬁed fragments were
conﬁrmed on a 1% agarose gel and puriﬁed with phenol-chloroform extraction
followed by ethanol glycogen precipitation or with E.Z.N.A. Cycle Pure Kit
(Omega), respectively. Puriﬁed DNA templates were used to perform T7 in vitro
transcription (600 ng per reaction for PCR fragment and 200–600 ng for linearized
plasmid) using increasing Mg2þ concentrations to optimize conditions. Tran-
scription solutions were incubated at 37  C for 3–4 h and the reaction was aborted
with 5 ml of 0.5M EDTA. Transcribed RNAs size and homogeneity were conﬁrmed
on 3.5–5% denaturing urea polyacrylamide gel. Positive RNA reactions were
pooled together and RNAs were puriﬁed by phenol:chloroform extraction followed
by precipitation (for each 30 ml reaction) with 70ml H2O, 5 ml of NaCl, 1 ml of
20 mgml 1 glycogen, 2 ml of 100mM EDTA, 350ml of cold 100% ethanol, stored at
 80  C for 30min, and then centrifuged for 20min at room temperature at
20,000g. The supernatant was removed and the pellet was allowed to air dry for 1 h.
Pellets were dissolved to a ﬁnal concentration of 1 mM in H2O DEPC.
Selective 20-hydroxyl acylation analysed by primer extension. RNA was
labelled with N-methylisatoic anhydride (NMIA) for selective 20-hydroxyl
acylation analysed by primer extension (SHAPE). RNA (36 ml of 1 mM stock) was
combined with 20 ml of H2O, followed by addition of 56 ml of 2 folding buffer
(200mM NaCl, 100mM HEPES, 0.2mM EDTA, pH 8.0). The reaction was heated
at 95 C for 3min, and then rapidly cooled on ice for 5min. The RNA was refolded
with the addition of 50 ml of refolding buffer (100mM NaCl, 50mM HEPES,
16.5mM MgCl2, pH 8.0). RNA solution was then distributed in 27 ml aliquots into
6 different tubes. 3 ml of DMSO, 32.5mM NMIA or 65mM NMIA dissolved in
100% DMSO were added to two of the six tubes. The reactions were heated at 37 C
for 45min, followed by ETOH precipitation. RNA pellets were resuspended in
15 ml of H2O treated with DEPC. Dephosphorylated primers (SHAPE, extREV9,
extREV8 extREV5_A extREV5_C) (Supplementary Table 2) were diluted to 3 mM
and 50 labelled with g32ATP (2 ml PNK Buffer A (New England Biolabs, NEB), 3 ml
of g32ATP (PerkinElmer, 10mCiml 1), 9 ml H2O, 1 ml PNK enzyme (New Eng-
land Biolabs). Reactions were incubated at 37 C for 30min, followed by the
addition of 1 ml of 0.5mM EDTA, pH 8.0, and incubated at 75 C for an additional
10min. Labelled primers were puriﬁed with QIAquick Nucleotide Removal Kit
(Qiagen) and eluted with 50 ml of water, bringing the ﬁnal concentration to 0.3 mM.
For 3’ extension reactions, sequencing reactions (1 ml of unmodiﬁed 1 mM RNA
combined with 2.5 mll of RNAse free water and 1 pmol of g32ATP labelled primer)
and SHAPE reactions (5ml of modiﬁed or DMSO treated RNA (B6 pmol)
combined with 1 pmol of g32ATP labelled primer) were each added with 6.1 and
8.1 ml, respectively, of the enzyme mix. For sequencing reactions additional 4.5 ml
ddNTP (5mM) (either A, G, C, or T) was added to the solution. The reactions were
incubated at 52 C for 1min, and then 0.5 ml of SuperScript reverse transcriptase III
(Invitrogen) was added to each reaction. The reactions were incubated for 10min
at 52 C, followed by the addition of 0.6 ml of 4M NaOH. The reactions were
heated for 5min at 95 C. Following heating, 14.5 ml of acid stop solution (432 ml
2X Urea Loading Buffer, 64ml 1M Tris) was added to each reaction, heated at
95 C for 5min and then allowed to cool at room temperature. Sequencing and
SHAPE reactions (8 ml loaded) were analysed on 8% acrylamide gels (17.5ml H2O,
5ml 10 X TBE, 10ml 40% 19:1 bis-acrylamide, 24 g urea, 500ml 10% ammonium
persulfate, 50ml TEMED). Gels were run for different time at 70W. Gels were then
dried and exposed to a phosphor plate overnight. The phosphor plates were
scanned using a Typhoon 600 imager.
SHAPE quantiﬁcation and structure modelling. SHAPE data were analysed and
quantiﬁed using Semi-Automated Footprinting Analysis (SAFA) program77.
Reactivity data were then incorporated as a shape constraint ﬁle in the
RNAstructure folding program (http://rna.urmc.rochester.edu/), and the 20 lowest
energy structures based on those constraints were generated. The RNA structure
models have been visualized using the Visualization Applet for RNA (VARNA)
program (http://varna.lri.fr/).
Statistical analysis. Statistical analyses and custom scripts were performed on R
(version R-3.0.3). Kaplan–Meier survival curves were performed using Stata and
JMP licensed software.
Data availability. GRO-seq data sets used in the study can be retrieved from the
Gene Expression Omnibus (GEO) with the accession numbers GSE47805 (sample
GSM1159895); GSE45822 (samples GSM1115995, GSM1115996, GSM1115997,
GSM1115998); GSE53964 (samples GSM1304424, GSM1366021, GSM1304426);
GSE41009 (samples GSM1006729, GSM1006731). Genomic coordinates of pre-
dicted paRNAs predicted in the CDH1 promoter and genome-wide are available at
https://ﬁgshare.com: doi.org/10.6084/m9.ﬁgshare.4858385.v2 (paRNAs in the
CDH1 promoter) and doi.org/10.6084/m9.ﬁgshare.4856630.v2 (genome-wide
predicted paRNA). All other data that support the ﬁndings of this study are
available from the corresponding author on request.
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